Dalton and colleagues [33] previously showed that bortezomib decreases FA/BRCA gene expression in multiple myeloma cells, and that NF-κB transcriptionally upregulates the FA/BRCA pathway. Here, NFKB1 is linked to plasma cell myeloma.